(Q44438917)

3 December 2017

Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. (English)

1 reference

3 December 2017

0 references

4

1 reference

3 December 2017

5

Leif Bertilsson

1 reference

3 December 2017

Rajaa A Mirghani

1

1 reference

PubMed ID

12743670

3 December 2017

Orjan Ericsson

series ordinal

2

1 reference

PubMed ID

12743670

3 December 2017

Gunnel Tybring

series ordinal

3

1 reference

3 December 2017

11 March 2003

1 reference

European Journal of Clinical Pharmacology

3 December 2017

1 reference

3 December 2017

59

1 reference

3 December 2017

1

1 reference

3 December 2017

23-28

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-003-0575-5

3 December 2017

0 references

cites work

Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Extrahepatic metabolism of drugs in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Cytochrome P-450 3A4: regulation and role in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Red wine-cisapride interaction: comparison with grapefruit juice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Identification and functional characterization of eight CYP3A4 protein variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Quinine disposition kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

In vitro forecasting of drugs which may interfere with the biotransformation of midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Effect of dose size on the pharmacokinetics of orally administered quinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Simultaneous determination of quinine and four metabolites in plasma and urine by high-performance liquid chromatography

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

21 January 2018

12 December 2020

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Can oral midazolam predict oral cyclosporine disposition?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Antimalarial pharmacokinetics and treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

The reproducibility of quinine bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0575-5

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

21 January 2018

1 reference

12 December 2020

Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.

1 reference

12 December 2020

Grapefruit juice has no effect on quinine pharmacokinetics

1 reference

12 December 2020

Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.

1 reference

12 December 2020

Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype

1 reference

12 December 2020

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1 reference

12 December 2020

Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.

1 reference

12 December 2020

Treatment of nocturnal leg cramps. A crossover trial of quinine vs vitamin E

1 reference

12 December 2020

Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450

1 reference

12 December 2020

In vivo modulation of CYP enzymes by quinidine and rifampin

1 reference

12 December 2020

Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators.

1 reference

12 December 2020

Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes

1 reference

12 December 2020

Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009

1 reference

12 December 2020

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

1 reference

12 December 2020

Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region

1 reference

12 December 2020

Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine

1 reference

12 December 2020

Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men

1 reference

12 December 2020

10.1007/S00228-003-0575-5

Identifiers

DOI

1 reference

3 December 2017

1 reference

PubMed ID

12743670